18 September 2017


("Sareum" or "the Company")

Sierra Oncology to host Key Opinion Leader call with Thomas Helleday, PhD on DNA Damage Response Targets, on Tuesday 19 September

Sareum Holdings plc (AIM: SAR), the specialist cancer drug discovery and development business, notes that Sierra Oncology, the licence holder advancing clinical cancer candidate SRA737, will host a Key Opinion Leader call with Thomas Helleday, PhD on the topic of "DNA Damage Response Targets Beyond PARP" focusing on clinical stage DDR targets in oncology, including Checkpoint kinase 1 (Chk1), on Tuesday, September 19 at 10:30 am Eastern Time (3:30pm UK time) – details below.

SRA737 is a potent, highly selective, orally bioavailable small molecule inhibitor of Chk1, a key regulator of important cell cycle checkpoints and central mediator of the DNA damage Response (DDR) network. Sierra Oncology holds exclusive and worldwide rights for SRA737, having licensed the programme from Sareum’s co-investment partner, the CRT Pioneer Fund, in September 2016. SRA737 is currently being investigated in two Phase 1 clinical trials in patients with advanced cancer.

The call will feature a presentation by distinguished scientist Thomas Helleday, PhD, the Torsten and Ragnar Söderberg Professor of Translational Medicine and Chemical Biology at Karolinska Institutet, Stockholm, Sweden, who will examine emerging data and current mechanistic understandings of the next generation of clinical stage DDR targets in oncology, including Chk1. In addition, he will review which drug targets are synergistic in combination with Chk1 inhibition, and also will discuss certain preclinical DDR targets currently generating interest in the field.

Sierra Oncology's Senior Vice President of Research, Christian Hassig, PhD, will provide a brief overview on the company's research and development strategy for SRA737, which has best-in-class potential and is currently in two Phase 1 clinical trials focused on enrolling patients with tumours identified to have genetic aberrations hypothesized to confer sensitivity to Chk1 inhibition via synthetic lethality, as a monotherapy or in combination.

The Press release from Sierra Oncology can be found by clicking here

Dial-In & Webcast Information

Domestic:            +1 800-289-0496

International:    +1 719-325-4826

Conference ID:  8310106

Webcast:             www.sierraoncology.com  

direct link: http://public.viavid.com/index.php?id=126208  


For further information, please contact: 

Sareum Holdings plc


Tim Mitchell

01223 497 700

WH Ireland Limited (Nominated Adviser and Co-Broker)

Chris Fielding / James Sinclair-Ford

020 7220 1666

Hybridan LLP (Co-Broker)


Claire Noyce

020 3764 2341

Citigate Dewe Rogerson (Media enquiries)


 Shabnam Bashir/ Mark Swallow/ David Dible

 020 7282 9571

Notes for editors: 

Sareum is a drug discovery and development company delivering targeted small molecule therapeutics, focusing on cancer and autoimmune disease, and licensing them to pharmaceutical and biotechnology companies at the preclinical or early clinical trials stage.

Sareum operates an outsourced research model, working with international collaborators and a world-wide network of research providers. Its most advanced programme (Chk1) commenced clinical trials in May 2016 and was licensed to NASDAQ-listed Sierra Oncology in September 2016.

SKIL® (Sareum Kinase Inhibitor Library) is Sareum's drug discovery technology platform that has so far produced the Company's Aurora+FLT3 and TYK2 kinase cancer and autoimmune disease research programmes, which are in the IND-enabling preclinical and lead optimisation stages respectively. SKIL® can also generate drug research programmes against other kinase targets.

Sareum Holdings plc is listed on the AIM market of the London Stock Exchange, trading under the symbol SAR. For further information, please visit www.sareum.co.uk

- Ends -